MedPath

VIMOVO

VIMOVO

Approved
DIN Number

02361701

Drug Class

Human

Market Date

Feb 4, 2011

Company
HC

xediton pharmaceuticals inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02361701
AIG Number0252870001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
M01AE52 NAPROXEN AND ESOMEPRAZOLE
Product Specifications
Dosage FormTablet (Immediate And Delayed-Release)
Route of AdministrationOral
AHFS Classification28:08.04.92
Health Canada Classification

ACTIVE INGREDIENTS (2)

ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE)Active
Strength: 20 MG
Monograph: ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE)
NAPROXENActive
Strength: 375 MG
Monograph: NAPROXEN

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.